Korean LG Life Sciences and Swiss Biopartners Announce Positive Phase III Results For Once-Weekly Somatropin Biosimilar
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's LG Life Science and Swiss Biopartners GmbH will separately file biologics license applications in early 2010 with U.S. FDA and EMEA for their jointly developed slow-release recombinant human growth hormone somatropin
You may also be interested in...
Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA
SEOUL - South Korea's LG Life Sciences completed its Phase III clinical trial of its slow-release recombinant human growth hormone somatropin weekly injection for treating adults with growth hormone deficiency, and is getting its biologics license application ready for U.S. FDA for the new formulation
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).